RBC
ABMD

Ronald Blue & Co’s Abiomed Inc ABMD Stock Holding History

Ronald Blue & Co’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$308K Hold
2,147
– – 0.01% 154
2017
Q1 		$268K Hold
2,147
– – 0.01% 170
2016
Q4 		$242K Buy
+2,147
New +$249K 0.01% 174

Other funds holding ABMD

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Ronald Blue & Co's ABMD Position: Q2 2017 in Review

Ronald Blue & Co held its Abiomed Inc (ABMD) position steady in Q2 2017 at 2,147 shares worth $308K. The position accounts for 0.01% of the portfolio, ranked #154.

Ronald Blue & Co first reported a position in ABMD in Q4 2016 and has held it in 3 quarters since. 303 funds tracked by Wall St. Rank hold ABMD as of Q2 2017.

  • Ronald Blue & Co held 2,147 shares of Abiomed Inc worth $308K as of Q2 2017.
  • Ronald Blue & Co left its Abiomed Inc share count unchanged in Q2 2017.
  • Abiomed Inc made up 0.01% of Ronald Blue & Co's portfolio in Q2 2017, its #154 holding.
  • Ronald Blue & Co first reported a position in Abiomed Inc in Q4 2016 and has held it in 3 quarters since.
  • 303 funds tracked by Wall St. Rank held Abiomed Inc as of Q2 2017.

Based on Ronald Blue & Co's 13F filing for Q2 2017, filed 28 Jul 2017.